摘要
目的观察罗格列酮对2型糖尿病(T2DM)患者的长期疗效及安全性。方法采用自身治疗前后对照的方法,42例合用磺脲类、双胍类和α糖苷酶抑制剂药物治疗3个月以上血糖控制不良的T2DM患者加服马来酸罗格列酮,随访36个月,观察治疗前后血糖、HbA1c、FIns、HOMAIR、ISI、血清高敏C反应蛋白(hsCRP)、Hb、谷丙转氨酶(GPT)、谷草转氨酶(GOT)、谷氨酰转移酶(γGT)等的变化。结果马来酸罗格列酮治疗组FPG、2hPG、HbA1c、FIns、hsCRP均较治疗前明显下降(P<0.01),且与时间成正比,约治疗9个月后疗效趋于稳定,GPT、GOT、γGT较治疗前明显下降(P<0.05);所见的不良反应为下肢水肿,发生率为4.8%,经对症处理后消失。结论马来酸罗格列酮能有效降低长期口服降糖药物控制不佳的T2DM患者的血糖水平,对因脂肪肝而致的肝脏酶谱的增高有治疗作用,有良好的安全性。
Objective To evaluate the efficacy and safety of rosiglitazone in type 2 diabetic patients with inefficacy of sulfonylurea,metformin and acarbose. Methods The therapeutic effects before and 3,6,9,12,24,36 months after rosiglitazone 4 mg/d were compared in 42 type 2 diabetic patients with the inefficacy of sulfonylurea,metformin and acarbose treatment for at least 3 month. Clinical variables included blood glucose, HbA1c, fasting insulin （Fins）, insulin sensitive index （ISI）, insulin resistance index （IRI）, high sensitivity C-reactive protein （hsCRP）, liver and renal functions. Results Compared with pre-treatment values, the levels of FPG, PPG, Fins, Pins, IRI, hsCRP and HbA1c were decreased, but ISI increased significantly in treatment group. Two cases （4.8%） had mild edema in the lower extremity, and diminished gradually with spironolactone treatment. No hypoglycemia and liver damage occurred. Conclusion The long-term addition of rosiglitazone maleate to the treatment of type 2 diabetic patients with the inefficacy of sulfonylurea, metformin and acarbose treatments is quite effective and safe.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2006年第3期166-168,共3页
Chinese Journal of Diabetes
关键词
马来酸罗格列酮
降糖药
糖尿病
2型
Rosiglitazone maleate
Drugs of antidiabetics
Diabetes meUitns,type 2
